| Management target | Net Profit 20.0% FY27 |
|---|
| Revenue growth | 21.9% YoY for Q1 FY27. |
|---|---|
| Margins | EBITDA margin at 22%, up 190bps YoY; PAT margin 14.2%. |
| Demand visibility | Strong domestic pharmaceutical market growth above 10% expected. |
| Management confidence | High; confident in meeting FY27 targets and outperforming IPM. |
Growth
Q1 Revenue at INR422Cr (+21.9% YoY); PAT at INR60Cr (+30.1% YoY); EBITDA margins expanded 190bps to 22%.
Outlook
Maintained FY27 guidance of 15% organic revenue growth and 20% PAT growth; recently commissioned new hormone facility.
Risks
Geopolitical Southeast Asia risks impacting raw material costs; volatility in input/ancillary expenses mentioned.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 21.9% (= BEAT)
- Guided 20% PAT growth → delivered 30.1% (= BEAT)
- Guided 20% EBITDA margin → delivered 22% (= BEAT)
Earnings Call Transcript filed with BSE, NSE: CORONA. Summary written with AI assistance from the document.
Corona Remedies Ltd: key numbers
- Share price
- ₹2,117.70
- Market cap
- ₹12,952 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 65.1×Sector 50.4×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 3.63%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Corona Remedies Ltd
All →Corona Remedies Capital Structure Change
Sepia Investments Limited, Sage Investment Trust, and Anchor Partners sold 2,629,880 equity shares of Corona Remedies Limited. This non-promoter stake sale is disclosed under SEBI SAST regulations.
Corona Remedies Price Movement Clarification
CORONA Remedies Limited clarified that the recent increase in its share trading volume is purely market-driven and no undisclosed price-sensitive information exists.
Corona Remedies Investor Presentation: Key Takeaways
Corona Remedies reported strong Q1FY27 performance with 21.9% revenue growth and 33.5% EBITDA growth, driven by its strategic shift towards chronic therapies which now contribute ~73.4% of revenue.
Corona Remedies Q1 FY27 Results: Net Profit ₹60.1 Cr, Up 30.1% YoY
Corona Remedies Ltd reported revenue from operations of ₹422.4 Cr (+21.9% YoY) and net profit of ₹60.1 Cr (+30.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹60.1 Cr · +30.1% YoY
Corona Remedies Earnings Call: Key Takeaways
Corona Remedies reported strong FY26 results, outperforming industry growth via specialty chronic segments and strategic acquisitions like Wokadine and the Bayer portfolio.
Corona Remedies Earnings Call: Key Takeaways
CORONA Remedies reported 17.3% FY26 revenue growth to ₹1,403.2 Cr, driven by chronic therapy focus and strategic acquisitions like Wokadine. Company maintain's 20.9% EBITDA margins.